Synthetic cannabinoid JWH-018 and psychosis: An explorative study

Drug and Alcohol Dependence

Volumn 117, Issue 2-3, 2011, Pages 152-157

  Every Palmer, Susanna ^a  

^a CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Cannabinoids; Designer drugs; Forensic psychiatry; JWH 018; Psychoses, substance induced; Psychotic disorders; Qualitative research; Spice

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; CANNABINOID; CANNABIS; NEUROLEPTIC AGENT; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; ARTICLE; CANNABIS SMOKING; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; DRUG LEGISLATION; DRUG SCREENING; DRUG TOLERANCE; DRUG USE; EXPLORATORY RESEARCH; HUMAN; MALE; NEW ZEALAND; PHYSICAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SEMI STRUCTURED INTERVIEW; SYMPTOM; WITHDRAWAL SYNDROME;

ADULT; CANNABINOIDS; HUMANS; INDOLES; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; NAPHTHALENES; NEW ZEALAND; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

CANNABIS;

EID: 79960313022     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.01.012     Document Type: Article

References (53)

1. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
2. Atwood B.K., Huffman J., Straiker A., Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br. J. Pharmacol. 2010, 160:133-140.
3. Aung M.M., Griffin G., Huffman J.W., Wu M., Keel C., Yang B., Showalter V.M., Abood M.E., Martin B.R. Influence of the N-1 alkylchain length of cannabimimetic indoles upon CB(1) and CB(2)receptor binding. Drug Alcohol Depend. 2000, 60:133-140.
4. Auwärter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. Spice and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass Spectrom. 2009, 44:832-837.
5. Banerji S., Deutsch C.M., Bronstein A.C. Spice ain't so nice [abstract]. Clin. Toxicol. (Phila.) 2010, 48:632.
6. Bebarta V.S., Varney S., Sessions D., Barry D., Borys D. Spice: a new " legal" herbal mixture abused by young active duty military personnel [abstract]. Clin. Toxicol. (Phila.) 2010, 48:632.
7. Boydell J., van Os J., Caspi A., Kennedy N., Giouroukou E., Fearon P., Farrell M., Murray R.M. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol. Med. 2006, 36:1441-1446.
8. Bühler B., Hambrecht M., Löffler W., an der Heiden W., Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 2002, 54:243-251.
9. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
10. Dresen S., Ferreirós N., Pütz M., Westphal F., Zimmermann R., Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J. Mass Spectrom. 2010, 45:1095-1232.
11. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2009. Understanding the 'Spice" phenomenon. Available at: Last checked 15 October, 2010. http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%2520Thematic%2520paper%2520%25E2%2580%2594%2520final%2520version.pdf.
12. Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH 018 may precipitate psychosis in vulnerable individuals. Addiction 2010, 105:1859-1860.
13. Fergusson D.M., Poulton R., Smith P.F., Boden J.M. Cannabis and psychosis. BMJ 2006, 332:172-175.
14. Foti D.J., Kotov R., Guey L.T., Bromet E.J. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalisation. Am. J. Psychiatry 2010, 167:987-993.
15. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. ACS 1964, 86:1646-1647. available at: http://pubs.acs.org/doi/abs/10.1021/ja01062a046. Last checked 10 October.
16. Green A.I., Tohen M.F., Hamer R.M., Strakowski S.M., Lieberman J.A., Glick I., Clark W.S. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 2004, 66:125-135.
17. Griffiths P., Sedefov R., Gallegos A., Lopez D. How globalization and market innovation challenge how we think and respond to drug use: 'Spice' a case study. Addiction 2010, 105:951-953.
18. Guimarães F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 1990, 100:558-559.
19. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 2005, 31:608-612.
20. Hermann D., Sartorius A., Welzel H., Walter S., Skopp G., Ende G., Mann K. Dorsolateral prefrontal cortex N-acetyl-aspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol. Psychiatry 2007, 61:1281-1289.
21. Howlett A.C., Breivogel C.S., Childers C.R. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004, 47:345-358.
22. Hudson S., Ramsey J., King L., Timbers S., Maynard S., Dargan P.I., Wood D.M. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in " herbal high" products. J. Anal. Toxicol. 2010, 34:252-260.
23. Huffman J.W., Zengin G., Wu M.J., Lu J., Hynd G., Bushell K., Thompson A.L.S., Bushell S., Tartal C., Hurst D.P., Reggio P.H., Selley D.E., Cassidy M.P., Wiley J.L., Martin B.R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem. 2005, 13:89-112.
24. Lamb H.R., Weinberger L.E., Gross B.H. Community treatment of severely mentally ill offenders under the jurisdiction of the criminal justice system: a review. Psychiatr. Serv. 1999, 50:907-913.
25. Leggett J.D., Aspley S., Beckett S.R.G., D'Antona A.M., Kendall D.A., Kendall D.A. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br. J. Pharmacol. 2004, 141:253-262.
26. Leweke F.M., Koethe D., Pahlisch F., Schreiber D., Gerth C.W., Nolden B.M., Klosterkötter J., Hellmich M., Piomelli D. S39-02 Antipsychotic effects of cannabidiol. Eur. Psychiatry 2009, 24:S207.
27. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
28. Mauri M.C., Volonteri L.S., De Gaspari I.F., Colasanti A., Brambilla M.A., Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemiol. Ment. Health 2006, 23(2):4.
29. Moore T.H.M., Zammit S., Lingford-Hughes A., Barnes T.R.E., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
30. Morgan C.J.A., Curran H.V. Effects of cannabidiol on schizophrenia-like symptoms in cannabis users. Br. J. Psychiatry 2008, 192:306-307.
31. Morgan C.J.A., Schafer G., Freeman T.P., Curran H.V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br. J. Psychiatry 2010, 197:285-290.
32. Müller H., Sperling W., Köhrmann M., Huttner H.B., Kornhuber J., Maler J.M. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 2010, 118:309-310.
33. Murray R.M., Morrison P.D., Henquet C., Di Forti M. Cannabis, the mind and society: the hash realities. Nat. Rev. Neurosci. 2007, 8:885-895.
34. New Zealand Department of Corrections The National Study of Psychiatric Morbidity in New Zealand Prisons 1999, available at http://www.corrections.govt.nz/research/national-study-psychiatric-morbidity-in-nz-prisons.html Last accessed 15 October 2010.
35. Piggee C. Investigating a not-so-natural high. Anal. Chem. 2009, 81:3205-3207.
36. Rais M., Cahn W., Van Haren N., Schnack H., Caspers E., Hulshoff Pol H., Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry 2008, 165:490-496.
37. Sobolevsky T., Prasolov I., Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 2010, 200:141-147.
38. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J. Psychiatry Neurosci. 2007, 32:30-52.
39. Soyka M. Substance misuse, psychiatric disorder and violent and disturbed behaviour. Br. J. Psychiatry 2000, 1761:345-350.
40. Swofford C.D., Kasckow J.W., Scheller-Gilkey G., Inderbitzin L.B. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr. Res. 1996, 20:145-151.
41. Teske J., Weller J.P., Fieguth A., Rothämel T., Schulz Y., Tröger H.D. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2010, 878:2659-2663.
42. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 1996, 42:201-207.
43. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Haishima Y., Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem. Pharm. Bull. 2009, 57:439-441.
44. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci. Int. 2010, 198:31-38.
45. United Nations Office on Drugs and Crime. World Drug Report, 2010. Available at Last accessed on 1 October 2010. http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf.
46. United States Drug Enforcement Administration, Office of Forensic Sciences, 2009. 'Spice'-plant material(s) laced with synthetic cannabinoids or cannabinoid mimicking compounds. Microgram Bulletin. 42(3). Available at: Last accessed 1 October 2010. http://www.justice.gov/dea/programs/forensicsci/microgram/mg0309/mg0309.html.
47. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156:319-327.
48. Vardakou I., Pistos C., Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 2010, 197:157-162.
49. Vearrier D., Osterhoudt K.C. A teenager with agitation: higher than she should have climbed. Pediatr. Emerg. Care 2010, 26:462-465.
50. Wilkins C., Sweetsur P. Exploring the structure of the illegal market for cannabis. De Economist 2006, 154:547-562.
51. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325:1199-1201.
52. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of " Spice Gold" Dtsch. Artzebl. Int. 2009, 106:464-467.
53. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimarães F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 2006, 39:421-429.